Skip to content

Join us on our journey to advance cell and gene therapies​

Cell & Gene Therapy companies

We leverage single-cell technologies and our best-in-class AI platform ScaiVision to capture complex or novel cellular states and predict biologically-relevant endpoints. We are using single-cell multiomics data to:

  • Optimize product manufacturing by donor/patient selection
  • Streamline quality assessment by comprehensive characterization of product quality
  • Inform patient management by prediction of efficacy or toxicity of cell therapy products

ScaiVision identifies T cell signature predictive of therapy response and ICANS in DLBCL

Deng et al. (2020), Nature Medicine
  • CAR-T cell products for 23 Diffuse Large B-Cell Lymphoma (DLBCL) patients
  • scRNAseq data from CAR T cells were used for analysis with ScaiVision to predict therapy response and neurotoxicity (ICANS)
  • ScaiVision predicts ICANS with 100% accuracy
  • ScaiVision detects the rare cell population described as IACs (ICANS-associated cells) by Deng et al.
  • ScaiVision signature cells fully stratify patients
  • ScaiVision: gene signatures associated with high toxicity in both CD4 and CD8 T cells.
  • ScaiVision predicts CR with 87.5% accuracy
  • ScaiVision finds specific cells and gene signatures that characterize successful infusion products
  • Identified cell type are consistent with Deng et al.’s findings.
Helping you speed up your therapy development and increase your success rate